M. Stabile, et al. PLOS One (2024) Link to Study
Subjects: Dogs with mild to moderate mobility disorders
Time Periods: 8 weeks, 4-week washout, 8-week crossover
Methodology: 2 groups
- Group 1–UC-II® in combination with Boswellia Serrata
- Group 2–Placebo
Findings: Group 2 saw improved mobility within 4 weeks.
Discussion of active ingredients and reasons for their use in this study:
"Undenatured type II collagen acts throuigh the interaction of the active epitopes of type II collagen with Peyer's patches by a mechanism known as oral tolerance, promoting the conversion of naive T cells into T regulatory (Treg) cells and the release of their anti-inflammatory cytokines into the joint, such as transforming growth factor-beta (TGF-beta), interleukin-4 (IL-4) and interleukin-10 (IL-10) [17]; while Boswellia serrata extracts appear to act by inhibiting leukotriene synthesis, production of pro-inflammatory cytokines, reduction of oxygen free radicals and inhibition of the complement system [19,20]. Thus, both substances may contribute to the modulation of the joint inflammatory response. There is considerable evidence to support the clinical efficacy of the two components when used separately or in association to other supplements in dogs with osteoarthritis [21-30], but no study has been carried out looking at the combined effect of the two components. To the authors' knowledge, this is the first study to test the effects of a feed supplement containing undenatured Type II Collagen (UC-II®) and Boswellia Serrata for managing mild to moderate mobility disorders in dogs."